# A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07744763/  
OnCo record `nct07744763` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Farletuzumab-exatecan in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.

## Summary

A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07744763 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 260 participants planned, started 2025-03-28 and due to reach its primary completion in 2027-03-28. Interventions recorded: SYS6041.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07744763
- Phase: 1/2
- Setting: A Multicenter, Open-label, Dose-escalation and Dose-expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Antitumor Activity of SYS6041 in Patients With Advanced Solid Tumors
- Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
- Enrolled: 260

## Sources

- ClinicalTrials.gov NCT07744763: https://clinicaltrials.gov/study/NCT07744763

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Farletuzumab-exatecan](https://onco.cc/drugs/farletuzumab-exatecan/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct07744763.json